TICKERNERD
Menu
TNGXTNGXHealthcare · Biotechnology

TNGX Stock Forecast: Tango Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$24
+1.57% on the day

The 13 Wall Street analysts covering Tango Therapeutics, Inc. hold a median 12-month price target of $40 — +67.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$4.0B
Ticker Nerd rank
41 / 100
Median analyst target
$40
Analysts covering
13
Total return, dividends reinvested
1W
−6.7%
1M
−17.7%
YTD
+169.5%
1Y
+240.7%
From 52W high
−27.4%
From 52W low
+275.5%
$6
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TNGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tango Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Growth
92
Volatility
50
Value
47
Quality
44
Issuance
37
Revisions
31
Size
28
Accruals
22

Momentum (97): The shares have been drifting up relative to others.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TNGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26TNGXHigh $69Median $40Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $24Median $40High $69

The green dot is the last close — the median target sits +67.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
18 Aug 2026HC Wainwright & Co.MaintainsBuy$66 → $68
12 Aug 2026GuggenheimMaintainsBuy$32 → $35
17 July 2026MizuhoMaintainsOutperform$36 → $40
17 July 2026MizuhoMaintainsOutperform—
15 July 2026JP MorganInitiatesOverweight$46
15 July 2026JP MorganInitiatesOverweight—
29 June 2026Canaccord GenuityMaintainsBuy$42 → $46
29 June 2026Canaccord GenuityMaintainsBuy—
26 June 2026JefferiesUpgradeBuy$27 → $60
26 June 2026JefferiesUpgradeBuy—
11 June 2026Canaccord GenuityMaintainsBuy—
9 June 2026Canaccord GenuityMaintainsBuy—
9 June 2026HC Wainwright & Co.MaintainsBuy—
8 June 2026Leerink PartnersMaintainsOutperform—
15 May 2026MizuhoMaintainsOutperform—
15 May 2026Piper SandlerDowngradeNeutral—
14 May 2026JefferiesDowngradeHold—
14 May 2026Leerink PartnersMaintainsOutperform—
14 May 2026WedbushMaintainsOutperform—
27 Apr 2026StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TNGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Tango Therapeutics, Inc. (TNGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−27.5×

Cheaper than 97% of US stocks

Price / sales
74.8×

Cheaper than 5% of US stocks

Price / book
8.8×

Cheaper than 12% of US stocks

EV / EBITDA
−22.6×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−253.4%

Higher than 10% of US stocks

Net margin
−229.9%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−21.3%

Higher than 30% of US stocks

Return on assets
−13.0%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TNGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNGXTango Therapeutics, Inc.$4.0B
41
DNLIDenali Therapeutics, Inc.$3.9B
64
VKTXViking Therapeutics, Inc.$3.9B
34
RCUSArcus Biosciences, Inc.$3.8B
58
IDYAIDEAYA Biosciences, Inc.$3.7B
83
IOVAIovance Biotherapeutics, Inc.$3.7B
88
ABCLAbCellera Biologics, Inc.$3.7B
67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tango Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNGX news & analysis

Tango Therapeutics: Promising Early Data, But A Long Road Ahead

Seeking Alpha · 16 Aug 2026neutral

Seeking Alpha reports that Tango Therapeutics' vopimetostat, combined with daraxonrasib, has produced an unusually strong early signal in pancreatic cancer, though from a very small, previously treated cohort. A planned front-line Phase 3 trial could expand the opportunity, but its design, timing, and regulatory path remain unsettled, with additional readouts needed across combinations, lung cancer, and CNS indications.

Why it matters — A TNGX watcher would care because the near-term value hinges on whether this early pancreatic signal develops into a larger, front-line opportunity and a broader PRMT5 franchise, or remains dependent on one limited dataset.

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

Zacks Investment Research · 12 Aug 2026negative

Tango Therapeutics shares fell 5% after reporting a wider-than-expected second-quarter loss, driven by higher operating expenses.

Why it matters — The stock decline reflects investor concern over rising costs, even as the company's pipeline progress continues to be a key area of focus.

Tango Therapeutics Announces Executive Chair Transition

GlobeNewsWire · 6 Aug 2026neutral

Tango Therapeutics announced that Dr. Barbara Weber, Executive Chairman of the Board of Directors, will be stepping down from her role in connection with other pursuits.

Why it matters — A change in executive board leadership can signal shifts in governance or strategy for the company, making it relevant for those following Tango Therapeutics.

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zacks Investment Research · 3 Aug 2026neutral

Zacks Investment Research reports that medical sector earnings are off to a strong start, and identifies four biotech companies positioned to potentially beat estimates in their upcoming quarterly results.

Why it matters — For TNGX watchers, the report signals a broadly favorable earnings environment for biotech companies in the medical sector heading into Q2 reporting season.

FAQ

Frequently asked questions about TNGX stock

What is the TNGX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Tango Therapeutics, Inc. have a median 12-month price target of $40, with estimates ranging from $24 to $69. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNGX stock a buy right now?

Of the 13 analysts covering Tango Therapeutics, Inc., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tango Therapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNGX?

As at 22 Aug 2026, Tango Therapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will TNGX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +67.5% from the last close, and Ticker Nerd's factor model ranks Tango Therapeutics, Inc. 41 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNGX stock forecast for 2030?

No analyst covering Tango Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $69 over the next 12 months.

How has TNGX stock performed over the past year?

Tango Therapeutics, Inc. returned +240.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tango Therapeutics, Inc. do?

Tango Therapeutics Inc. is a biotechnology company focused on discovering and developing precision oncology therapies.

What is the latest news on TNGX?

The most recent item we track (Seeking Alpha, 16 Aug 2026): "Tango Therapeutics: Promising Early Data, But A Long Road Ahead". Seeking Alpha reports that Tango Therapeutics' vopimetostat, combined with daraxonrasib, has produced an unusually strong early signal in pancreatic cancer, though from a very small, previously treated cohort. A planned front-line Phase 3 trial could expand the opportunity, but its design, timing, and regulatory path remain unsettled, with additional readouts needed across combinations, lung cancer, and CNS indications.

Company

About Tango Therapeutics, Inc.

Tango Therapeutics Inc. is a biotechnology company focused on discovering and developing precision oncology therapies. The company applies synthetic lethality and target discovery approaches to identify cancer dependencies that can be addressed with medicines designed for specific tumor types. Its current pipeline centers on programs in oncology, including PRMT5 inhibitor candidates aimed at cancers such as pancreatic, lung, and brain tumors, along with research efforts tied to tumor suppressor gene loss and other genetically defined patient populations. Tango Therapeutics Inc. operates in the clinical-stage drug development segment, where its work contributes to the broader precision medicine market by advancing targeted approaches intended to improve cancer treatment specificity. The company is headquartered in Boston, Massachusetts, and is positioned within the life sciences sector as a developer of innovative therapeutic candidates for patients with high unmet medical need.

CEO Dr. Malte Peters M.D. · 137 employees · United States · https://www.tangotx.com